Chongqing Three Gorges Central Hospital
12
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia
Role: collaborator
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Role: collaborator
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Role: collaborator
NHFOV as Primary Support in Very Preterm Infants With RDS
Role: collaborator
Basilar Artery Occlusion Chinese Endovascular Trial
Role: collaborator
Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma
Role: collaborator
Time Window for Ischemic Stroke First Mobilization Effectiveness
Role: collaborator
NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)
Role: collaborator
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Role: collaborator
Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer
Role: collaborator
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD
Role: collaborator
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
Role: collaborator
All 12 trials loaded